Business Segments · Total Assets
Established Pharmaceuticals — Total Assets
Abbott Established Pharmaceuticals — Total Assets increased by 3.5% to $3.67B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 6.3%, from $3.45B to $3.67B.
Analysis
StatementSegment
CategoryEfficiency
SignalContext dependent
VolatilityStable
First reportedQ4 2016
Last reportedQ1 2026Apr 29, 2026
Rolls up toTotal Assets
How to read this metric
An increase in assets relative to sales may indicate declining asset turnover or heavy investment in working capital, while a decrease may signal improved asset utilization or divestitures.
Detailed definition
This metric represents the aggregate value of all resources, including inventory, accounts receivable, property, and int...
Peer comparison
Comparable to 'Segment Assets' reported by diversified healthcare and pharmaceutical companies to show the scale and capital footprint of individual business units.
Metric ID:
abt_segment_established_pharmaceuticals_total_assetsHistorical Data
9 periods
| Q4 '21 | Q4 '22 | Q4 '23 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|
| Value | $2.79B | $2.88B | $3.12B | $3.09B | $3.45B | $3.73B | $3.73B | $3.54B | $3.67B |
| QoQ Change | — | +3.4% | +8.2% | -1.0% | +11.7% | +8.2% | -0.1% | -5.1% | +3.5% |
| YoY Change | — | +3.4% | +8.2% | -1.0% | — | — | — | +14.7% | +6.3% |
Range$2.79B – $3.73B
CAGR+14.6%
Avg YoY Growth+6.3%
Median YoY Growth+6.3%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Abbott's established pharmaceuticals — total assets?
- Abbott (ABT) reported established pharmaceuticals — total assets of $3.67B in Q1 2026.
- How has Abbott's established pharmaceuticals — total assets changed year-over-year?
- Abbott's established pharmaceuticals — total assets increased by 6.3% year-over-year, from $3.45B to $3.67B.
- What does established pharmaceuticals — total assets mean?
- The total value of all resources and assets dedicated to the Established Pharmaceuticals business segment.